YuTian Medical Investment Management

YuTian Medical Investment Management is a Chinese healthcare investment and management firm focused on introducing advanced international medical technologies to the Greater China region. The company serves as the strategic partner and a major shareholder of Ventripoint Diagnostics, a Canadian leader in AI-driven echocardiography. YuTian holds the exclusive distribution and licensing rights for Ventripoint's Knowledge-Based Reconstruction (KBR) technology, which it markets in China under the Quantitative Analysis System (QAS) brand. The company operates through several subsidiaries, including Hefei KBR Hi-tech, to manage regulatory approvals, clinical training, and commercial distribution. Their primary focus is providing cost-effective, MRI-equivalent cardiac monitoring solutions for heart disease, pulmonary hypertension, and congenital heart conditions. By leveraging a network of tier-1 distributors, YuTian facilitates the adoption of AI diagnostic tools in top-tier Chinese hospitals.